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Abstract: Space flight (SF) and dust inhalation in habitats cause hypertension whereas in SF 
(alone) there is no consistent hypertension but reduced diurnal blood pressure (BP) variation 
instead. Current pharmaceutical subcutaneous delivery systems are inadequate and there is impair-
ment in the absorption, metabolism, excretion, and deterioration of some pharmaceuticals. Data 
obtained from the National Aeronautics and Space Administration through the Freedom of Infor-
mation Act shows that Irwin returned from his 12-day Apollo 15 mission in 1971 and was admin-
istered a bicycle stress test. With just three minutes of exercise, his BP was 275/125 mm Hg 
(heart rate of only 130 beats per minute). There was no acute renal insult. Irwin’s apparent 
spontaneous remission is suggested to be related to the increase of a protective vasodilator, and 
his atrial natriuretic peptide (ANP) reduced with SF because of reduced plasma volume. With 
invariable malabsorption and loss of bone/muscle storage sites, there are significant (P  0.0001) 
reductions of magnesium (Mg) required for ANP synthesis and release. Reductions of Mg and 
ANP can trigger pronounced angiotensin (200%), endothelin, and catecholamine elevations 
(clearly shown in recent years) and vicious cycles between the latter and Mg deficits. There is 
proteinuria, elevated creatinine, and reduced renal concentrating ability with the potential for 
progressive inflammatory and oxidative stress-induced renal disease and hypertension with 
vicious cycles. After SF, animals show myocardial endothelial injuries and increased vascular 
resistance of extremities in humans. Even without dust, hypertension might eventually develop 
from renovascular hypertension during very long missions. Without sufficient endothelial protec-
tion from pharmaceuticals, a comprehensive gene research program should begin now.
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“The farther backward you can look, the farther forward you are likely to see.”
—Winston Churchill
Introduction
Even without radiation the endothelium is vulnerable to dysfunction/injuries with space 
flight (SF) because of oxidative stress involving both the cardiovascular system as well 
as the systemic circulation in the “Apollo 15 space syndrome.”1 This syndrome, which 
I described, was experienced by both Irwin and Scott on the first of three excursions 
to the lunar surface, even prior to dust inhalation in that habitat. My syndrome was 
characterized by very painful, apparently swollen, fingertips possibly secondary to 
peripheral vasospasm and compression by fluid trapped distally. Therefore it can be 
a warning that coronary vasospasm with ischemia (possibly silent) might also exist, 
predisposing the person to a myocardial infarction.International Journal of Nephrology and Renovascular Disease 2009:2 52
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Similarly vasoconstriction of systemic blood vessels 
could be the underlying mechanism of a decrease of calf 
blood flow of 40%. Measurements taken between 4–12 SF-
days showed calf vascular resistance doubling. The blood 
pressure (BP) increased during SF.2 With SF, vicious 
cycles can occur between magnesium (Mg) ion deficits and 
catecholamine elevations and also between catecholamine 
elevations and ischemia. Furthermore vicious cycles can 
also develop between reduced nitric oxide (NO), coronary 
vasospasm with turbulence, and endothelial injuries.3
Through information obtained by the Freedom of 
Information Act (FOIA), I acquired bicycle stress test 
data regarding Irwin on Apollo 15 showing extraor-
dinary hypertension. The stress test data indicated a 
BP  275/125 mm Hg with a heart rate of only 132 per 
minute after just three minutes of exercise. This test was 
probably performed on the day after his return from the 
12-day mission. The resting BP was not shown, but at one 
minute the BP was 250/125, with the same heart rate. There 
was no evidence of an acute renal insult. On the other hand it 
is noteworthy that Shepard’s bicycle stress test data, on the 
day after his return from the Apollo 14 mission, revealed a 
relatively normal response, with a BP of 200/75 at the same 
heart rate as Irwin’s, but not reaching this level (132 per 
minute) until 13 minutes of exercise.
One mechanism for this discrepancy could be related to 
the variation in the chemical composition of the dust inhaled 
at various lunar landing site habitats.4 Conrad’s stress test 
data – the only other deceased moon walker (Apollo 12) – is 
not available, after a “careful search” by National Aeronautics 
and Space Administration (NASA) in response to my FOIA 
request in 2008.
On the stress test, on the day of his return, Irwin showed 
“cyanosis of the finger tips” from the 18th–20th minutes 
with a BP of 200/90, consistent with venous blood trapped 
distally, which supports my syndrome on the likelihood of 
space syndrome. I postulated that the severe hypertension 
was a complication of dust inhalation. The inhalation had 
occurred for a total of almost seven days; about 40 hours in 
the lunar habitat, two days orbiting the moon, making the 
survey, dust brought into the command module and the three-
day journey home.4 The vulnerability to endothelial injuries 
is far greater in males and in addition the endothelium does 
not heal adequately after the age of 30 years.3 Furthermore, 
assuming that some day the problems of hypertension 
related to dust, brought from the habitats on the moon, will 
be resolved with removal of even ultrafine dust,4 there are 
the problems stemming from depletion of the reservoirs for 
water ie, primarily in skeletal muscle and Mg reservoirs in 
muscle and bone (about 60% in the latter). This loss stems 
from hypokinesia (decreased movement) compounded by 
decreased thirst and is conducive to oxidative stress-induced 
renovascular hypertension.5 To prevent this, gene therapy 
may be necessary6,7 since there are multiple problems with 
pharmaceuticals; there is invariable SF-malabsorption,8 
deterioration of some medications no longer meeting United 
States Pharmacopeia (USP) standards9 and impairment 
in pharmaceutical metabolism and excretion because of 
potential SF injuries to the liver10 and kidneys.11
Whereas Fritsch-Yelle and colleagues12 found reduced BP 
on shuttle missions of 5–10 days; Shiraishi and colleagues13 
found that the waking BP was not different from preflight 
levels. On the other hand Watenpaugh and colleagues2 found 
that SF BP increased in comparison to postflight supine levels 
and they suggested that premission differences in baseline 
conditions could account for these discrepancies. However 
the absence of a significant drop (10%) in nocturnal BP12,13 
indicates that those during SF are “nondippers,” which 
portends to renal disease as discussed below.
Potential renovascular  
hypertension
There is a predisposition for progressive oxidative stress-
induced renal disease5 intensified by atrial natriuretic 
peptide (ANP) deficiencies6,14–16 with a 40% reduction on 
Spacelab 2 and excessive levels of catecholamines1,3,4,17,18 
and the combination of endothelin19 and significant 
angiotensin I elevations (P  0.0001)17 conducive to sustained 
renal vasoconstriction.20,21
There is a potential synergism regarding endothelin and 
angiotensin II blockade which has been shown to improve 
endothelial function. Blockade of both has also been 
shown to increase renal blood flow in healthy subjects,21 
but, as emphasized above, pharmaceuticals can not be 
utilized. Proteinuria, considered an expression of endothe-
lial dysfunction22 and a strong predictor of renal disease 
progression,23–25 with stimulation of endothelin expression in 
renal cells,19 was shown after space missions.17,18 Proteinuria 
was more pronounced after prolonged missions but disap-
peared during the recovery period17 possibly related to 
reductions back to premission catecholamine levels.23 SF 
reductions of vascular endothelial growth factor (VEGF) 
from thrombocytopenia with platelet aggregation from endo-
thelial dysfunction26 and impaired VEGF expression as a 
result of SF insulin resistance27 would impair capillary repair 
in damaged glomeruli and contribute to proteinuria.28,29 International Journal of Nephrology and Renovascular Disease 2009:2 53
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Furthermore the reduced diurnal variabilities in blood 
pressures (“nondipper”) as noted previously increases the 
risk of renal dysfunction. The mechanisms may be related 
to increased sympathetic nervous system activity and 
possibly insulin resistance, both of which have been shown 
with SF.1,3,4,17,30 Many cosmonauts have shown higher levels 
of blood creatinine during and after SF in comparison to 
their preflight levels, and there is decreased concentrating 
ability after SF.17 It was also found that urine osmolarity 
in response to fluid deprivation was consistently lower 
after flight than before, but only if the flight lasted more 
than 30 days.17
Studies after short missions and hypokinesia of rat 
heart tissue showed narrowing of the small vessels, some 
occlusions, and endothelial projections conducive to 
increased permeability.18,31 Leach Huntoon and colleagues17 
postulated that increased permeability of capillary mem-
branes may be the most important mechanism for SF-induced 
plasma volume reduction of 10% conducive to endothelial 
injuries with vicious cycles and angiotensin elevations and 
reduced secretion of ANP.
Too much or too little exercise will deplete Mg ions3 
that are antioxidants as well as calcium (Ca) blockers.27 On 
spacecraft, it has been postulated that there may be a shift of 
Ca into the cells complicating high carbon dioxide levels.4 
This may contribute to Ca overload of the mitochondria as 
shown in rats after SF.31 Contributing to SF oxidative stress32 
and in turn Ca overload is the necessity of 100% oxygen for 
1–2 hours prior to a space walk to prevent decompression 
sickness.4 Mg could reduce this oxidative stress,27,33 but 
there is no suitable subcutaneous delivery device for Mg, 
since at this time a reliable subcutaneous microchip device 
can’t be replenished.27 Invariable SF malabsorption and 
reduced storage sites could be responsible for significant SF 
Mg deficits (P  0.0001) after shuttle missions.17 In addi-
tion to the 200% increase of plasma angiotensin after, for 
example, the Skylab flights of up to 84 days,17 there could be 
the predisposition for an active intrarenal renin–angiotensin 
system. SF is conducive to increased angiotensin effects 
from both reduced plasma volume17 and ANP deficits with 
reduced NO15 and also from Mg ion deficits. Magnesium 
also affects the synthesis and release of ANP.16 An intrarenal 
renin–angiotensin system resulting from SF-reduced NO 
could contribute to chronic kidney disease stemming from 
inflammation both directly and through interaction with 
oxidative stress mechanisms.17,18,32,34,35 Elevated sympathetic 
nerve activity has been shown unequivocally in patients 
with renovascular hypertension,36 but until a few years ago 
the catecholamine levels were not thought to be elevated 
with SF. This concept has now been shown to have been 
incorrect. Christensen and colleagues,37 for example, have 
shown that plasma norepinephrine (NE) and plasma renin 
activity38 were increased even to levels above those of the 
seated ground-based position. Plasma NE was approxi-
mately twice the value of the supine position on the ground, 
predisposing those in SF to nondipping, as noted above.30 
Furthermore, it was stated that the reason for this was 
unclear. Certainly one mechanism may be the reductions 
of SF Mg ion levels with, in turn, elevations of catechol-
amines, along with elevations of angiotensin and aldoste-
rone (P = 0.0008) with ongoing vicious cycles.1,3,4,17,18,27,39 
Magnesium may also provide protection against the renal 
damaging effects of aldosterone, predisposing the person 
to fibrosis.39–41
Gender selection
Pertaining to the predisposition for renovascular hyperten-
sion, young females have several clear advantages. The 
endothelium is not adequately repaired after the age of 
30 years,3 and the cardiovascular mortality rate is six times 
higher in males than females under the age of 35 years. This 
could be related not only to estrogen’s vascular advantages3 
and probably to the fact that males have no physiological 
way of losing iron, predisposing them to oxidative stress, but 
also could be related to other clear advantages in females. 
The levels of ANP in females are approximately twice those 
of young men.42 During the 438-day mission of Polyakov 
and after just five months in space, his cyclic guanosine 
monophosphate (cGMP) levels were undetectable, which 
supports my hypothesis.3,43 cGMP is a second messenger 
of both NO and ANP, and Polyakov’s cGMP did not return 
to premission levels until three months after this mission. 
The cGMP–signaling pathway has been postulated as an 
important regulator of renal physiology.15 ANP receptors 
are expressed on the surface of renal endothelial cells,15 and 
ANP inhibits renin release and can reduce renal damage from 
an ischemic insult.38
Metabolic balance studies of young adults showed that 
with marginal intakes of Mg, males tended to be in nega-
tive Mg balance whereas females remained in equilibrium. 
Catecholamine levels in males, in turn, are therefore higher 
with vicious cycles between Mg ion deficits and catechol-
amine elevations39 (Figure 1). After SF of only 18–22 days, 
rats showed an increased activity of the juxtaglomerular 
apparatus18 and similarly, experimental Mg deficiency has 
been shown to cause hypertrophy of this structure, resulting International Journal of Nephrology and Renovascular Disease 2009:2 54
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in aldosterone secretion, and in turn, an increased Mg loss 
and another vicious cycle.27,39 VEGF levels are significantly 
higher during the formative stage (early teens) in females, 
although not in adulthood,44 which would enhance repair 
of the endothelium as well as increase the development of 
collateral circulation.28,29
Gene therapy
How can we offset the SF reductions in cGMP43 to maintain 
endothelial function by utilizing novel pharmacological 
compounds to prevent renal disease and in turn hyperten-
sion? How can we break self-perpetuating vicious cycles? 
Oxidative stress involving the kidneys and blood vessels 
triggers hypertension, whereas conversely hypertension 
has been shown to cause oxidative stress and inflammation 
in the kidney and cardiovascular tissue of experimental 
animals.45 With very long missions, gene therapy may be 
the only option even without consideration of renal com-
plications.46 Gene therapy has been proposed, for example, 
to prevent invariable space anemia.7 This, therefore, could 
be of vital importance in preventing ANP deficiencies.6 
There is a 10% red blood cell mass loss within one week 
of entering space.17 Anemia may contribute to endothelial 
dysfunction by reducing oxygen delivery and intensifying 
oxidative stress since red blood cells have important 
antioxidant functions.47 In addition there are SF reduc-
tions in platelets, the primary source of VEGF, which, in 
turn, play an important role in angiogenesis, function, and 
repair of the endothelium.27 With SF there are reductions 
of water because of reduced thirst and loss of storage sites 
for water and Mg, and an impairment in red blood cell 
production. Therefore there is a reduction of three natural 
antioxidants conducive to endothelial dysfunction.1,3,4,48,49 
Furthermore, there is no subcutaneous device available to 
replenish Mg.27
Without the availability of pharmaceuticals for use in 
SF, there is no alternative but the use of gene therapy. In 
addition to its use to correct invariable SF anemia,7 gene 
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Figure 1 Proposed mechanisms showing how decreased atrial natriuretic peptide can cause severe hypertension secondary to dust inhalation, microgravity, and hypokinesia.
Abbreviations: catecholamines, epinephrine, norepinephrine, increased by dust;    Vc, vessel constriction;   VD, vessel dilatation;  Mg, magnesium ions;   ANP,  atrial natriuretic peptide; 
hypokinesia, decreased movement; angiotensin, angiotensin effect, increased by dust; NO, nitric oxide (endothelial derived relaxing factor); e, endothelin, increased by dust.International Journal of Nephrology and Renovascular Disease 2009:2 55
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therapy studies have been conducted to reduce BP.6,50,51 NO 
is generated by NO synthase (NOS) enzymes and NOS gene 
transfer has been shown to reverse endothelial dysfunction in 
several diseases including hypertension and atherosclerosis. 
In addition NOS gene therapy has been shown to improve 
renal function and since NO is antifibrotic, this therapy 
may reduce the potential for renal fibrosis complicating 
aldosterone excess.40,52 A major stumbling block, however, 
has been finding a suitable vector to deliver the gene to the site 
of action and this may require several years (possibly decades) 
of SF research involving vector studies with progressively 
wider applications.53
A number of viruses have been developed for gene 
transfer but the focus has been primarily on retroviruses, 
adenoviruses, adeno-associated viruses, and lentiviruses. 
The latter are currently of great interest; they are a type 
of retrovirus that can infect both dividing and nondivid-
ing cells because their virus “shelf” can get through the 
intact membrane of the nucleus of the target cell. How-
ever because of persistent serious immune reactions with 
viruses, some researchers are directing their investigations 
to nonviral gene delivery. For example liposomal gene 
transfer has been investigated but there is a relatively low 
level of gene expression compared with that achieved from 
viral vectors.52
It has been emphasized52 that gene therapy has not proven 
to be nearly as successful as had been predicted, which may 
be due to only transient transfection efficiencies. In addition 
if the expression of NOS gene therapy is not tightly regu-
lated to the target site, there is the potential complication of 
pronounced hypotension with impending shock. McCarthy 
and colleagues52 conclude, by stating that although thousands 
of patients have been treated with gene transfer therapies, 
reproducibility of positive results has yet to be demonstrated 
conclusively.
I have stressed that one of the major concerns with SF is 
the vulnerability of the endothelium and, therefore, research 
must include the correction of ANP, NO, VEGF, and red 
blood cell deficiencies, the latter because of its antioxidant 
effect; this effect is shared by Mg administration,33 which also 
has an anti-inflammatory and antifibrotic effect, and can pre-
vent aldosterone-induced renal dysfunction (proteinuria).40 
Since transfection efficiency may be temporary,52 gene 
therapy will have to be repeatedly reevaluated, depending 
upon the length of the mission. This will involve regularly 
scheduled diagnostic evaluation tests. How complex will 
these tests be and how much equipment and personnel will 
be required?
The gravity on the moon is 1/6 G whereas Mars is 0.38 G. 
Investigators have argued for decades as to how much 1 G 
is tolerable. Since we have Earth genes, I believe that any 
fraction 1 G may be ultimately intolerable. There is a 
solution, but we are only at the threshold of a process that 
may require many decades of gene therapy research before 
we are ready to embark on very long missions or colonize 
other planets. Is it “our destiny to colonize” before this 
research is complete? Some animals that spend all their 
lives in caves can’t adapt to the outside. Are we spared the 
restrictions of Nature? We share at least 80% of the same 
genes as rats.
Conclusions
Even though with relatively short missions (six months), the 
mean 24-hour BP is not elevated unless there is hyperten-
sion from inhalation of dust in the habitats without adequate 
protection devices, it seems reasonable to speculate that 
ultimately, astronauts will develop renovascular hyperten-
sion unless gene therapy is utilized. Until a suitable replen-
ishable subcutaneous device is developed, Mg, necessary 
for the synthesis as well as the release of ANP, cannot be 
administered. Space missions of considerable length are more 
likely to succeed with a female crew. In addition to ongoing 
pharmaceutical research, a comprehensive gene research 
program should begin now. Specifically gene therapy may 
be necessary to suppress activity of an upregulated intrarenal 
renin–angiotensin system.
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